In breast cancer, increased serum levels of YKL-40 were found in 19% of patients with primary cancer (Johansen et al, 2003) and 30% of patients with metastatic cancer (Jensen et al, 2003), supporting the notion that YKL-40 is associated with cancer aggressiveness. Here, CHI3L1 is linked to cancer.